
Another Potential Food Allergy Treatment is Snapped Up by Big Pharma
Eli Lilly’s $2.875 billion Merida acquisition signals Big Pharma’s growing interest in biotechs developing next-generation food allergy treatments. The post Another Potential Food Allergy Treatment is Snapped Up by Big Pharma appeared first on SnackSafely.com .










